
Replimune Group REPL
$ 14.01
-2.1%
Quarterly report 2024-Q4
added 02-12-2025
Country |
![]() |
IPO year |
2018 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
CEO |
Mr. Philip Astley-Sparke |
Employees in the company |
122 |
Shares |
66.6 M |
Market Cap[1] |
$ 933 M |
EBITDA (LTM) |
$ -236 M |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.